INmune Bio (NASDAQ:INMB) Given “Sector Underperform” Rating at Scotiabank

INmune Bio (NASDAQ:INMB)‘s stock had its “sector underperform” rating reaffirmed by research analysts at Scotiabank in a note issued to investors on Tuesday, MarketBeat.com reports.

INmune Bio Trading Up 10.4%

Shares of INMB stock traded up $0.25 during trading hours on Tuesday, reaching $2.61. The company’s stock had a trading volume of 4,699,962 shares, compared to its average volume of 778,332. INmune Bio has a one year low of $1.89 and a one year high of $11.64. The stock has a market capitalization of $61.43 million, a P/E ratio of -1.35 and a beta of 1.34. The firm’s fifty day simple moving average is $6.88 and its 200 day simple moving average is $7.23.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). The business had revenue of $0.05 million during the quarter. As a group, equities research analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Trading of INmune Bio

Several hedge funds and other institutional investors have recently made changes to their positions in INMB. Rhumbline Advisers raised its stake in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after buying an additional 2,409 shares during the last quarter. Jane Street Group LLC bought a new position in shares of INmune Bio during the first quarter valued at $142,000. PharVision Advisers LLC bought a new position in shares of INmune Bio during the first quarter valued at $135,000. Focus Partners Advisor Solutions LLC purchased a new position in INmune Bio in the first quarter worth about $91,000. Finally, Royal Bank of Canada grew its holdings in shares of INmune Bio by 44.8% during the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock valued at $233,000 after buying an additional 9,236 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.